PhageTech, Inc., an Irvine, CA-based development stage company with a platform that employs a bacteriophage substrate for detecting analytes in urine, blood and most any other body fluid, raised $2.4m in Series A funding.
The round was co-led by Mark IV Capital and Black River Investments.
The company intends to use the funds to complete development and FDA clearance of its PhageTech Biosensor™ technology.
Led by CEO Richard Henson, PhageTech develops biosensors which aim to enable early detection of cancers and other diseases while making disease detection instantaneous.
Developed with NIH funds at the University of California, Irvine, the PhageTech Biosensors will be interfaced with portable readers enabling near patient testing in under one minute providing physicians with real-time valuable information for quicker diagnoses, treatment and improved outcomes.